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This study evaluated the antifungal activities of synthetic naphthoquinones against opportunistic and dermatophytic
fungi and their preliminary mechanisms of action. The minimum inhibitory concentrations (MICs) of four synthetic
naphthoquinones for 89 microorganisms, including opportunistic yeast agents, dermatophytes and opportunistic
filamentous fungi, were determined. The compound that exhibited the best activity was assessed for its action against
the cell wall (sorbitol test), for interference associated with ergosterol interaction, for osmotic balance (K+ efflux) and for
membrane leakage of substances that absorb at the wavelength of 260 nm. All tested naphthoquinones exhibited
antifungal activity, and compound IVS320 (3a,10b-dihydro-1H-cyclopenta [b] naphtho [2,3-d] furan-5,10-dione)-dione)
demonstrated the lowest MICs across the tested species. The MIC of IVS320 was particularly low for dermatophytes
(values ranging from 5–28 μg/mL) and Cryptococcus spp. (3–5 μg/mL). In preliminary mechanism-of-action tests, IVS320
did not alter the fungal cell wall but did cause problems in terms of cell membrane permeability (efflux of K+ and
leakage of substances that absorb at 260 nm). This last effect was unrelated to ergosterol interactions with the
membrane.
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The recent high incidence of fungal infections is due to
the increased number of immunocompromised patients
who are infected with HIV or have undergone organ
transplantation or chemotherapy [1]. Although effective
antifungal agents are currently available, side effects such
as toxicity, drug interactions, inadequate pharmacokinetic
properties and the development of resistance have been
reported [2]. Therefore, new active entities that are safer,
more potent and broad spectrum are highly desired as
antifungal agents.
Among natural substances, naphthoquinones (found in
bacteria, fungi, animals and plants) have attracted interest
in recent years due to both their importance in vital
biochemical processes and their several known biological
activities, such as antitumor, antibacterial and antiviral [3].* Correspondence: joao.souza@inpa.gov.br
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unless otherwise stated.Indeed, a series of studies have demonstrated that naph-
thoquinone derivatives exhibit antifungal activity [4,5].
Additionally, the antifungal activity of four synthesized
compounds was reported against six species of Candida
isolated from the oral cavities of patients with removable
prostheses [6].
In this work, the antifungal activities of the compounds
2,2-dimethyl-2,3-dihydronaphtho [2,3-b] furan-4,9-dione,
2,2-dimethyl-2,3-dihydronaphtho [1,2-b] furan-4,5-dione,
3a,10b-dihydro-1H-cyclopenta [b] naphtho [2,3-d] furan-
5,10-dione)-dione and 7,9a-dihydro-6bH-cyclopenta [b]
naphtho [2,1-d] furan-5,6-dione were evaluated against 89
fungal cultures, including 29 opportunistic yeasts, 40 fila-
mentous fungi and 20 opportunistic dermatophytes. The
mechanism of action of the compound with the most ef-
fective antifungal activity was investigated using Candida
albicans strain ATCC 36232.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Naphthoquinones
The compounds used in this study were the naphthoqui-
nones IVS320 (3a,10b-dihydro-1H-cyclopenta [b] naphtho
[2,3-d] furan-5,10-dione)-dione), IVS322 (7,9a-dihydro-
6bH-cyclopenta [b] naphtho [2,1-d] furan-5,6-dione),
nor-α-lapachone (2,2-dimethyl-2,3-dihydronaphtho [2,3-b]
furan-4,9-dione) and nor-β-lapachone (2,2-dimethyl-2,3-
dihydronaphtho [1,2-b] furan-4,5-dione) (Figure 1). These
compounds were synthesized by the Developing Biologic-
ally Active Molecules and Methods for Organic Synthesis
research group, Department of Organic Chemistry, Uni-
versidade Federal Fluminense-UFF, as described by Freire
et al. [6]. A stock solution (2 mg/mL) of each compound
was prepared and then diluted in RPMI 1640 (Sigma-
Aldrich Co., St. Louis, MO, USA) to the required concen-
trations for the assays.
Microorganisms
Eighty-nine cultures (Table 1) from the Collection of
Microorganisms belonging to the National Institute of
Amazon Research-INPA were used in this study. The
cultures were preserved in mineral oil, and subcultures
were maintained in Sabouraud medium to ensure purity
and viability until the testing was performed. A culture
of C. albicans (36232) from the American Type Culture
Collection (ATCC) was used as a control for the suscep-
tibility testing and mechanism-of-action studies.
Antifungal activity assay
Minimum inhibitory concentration (MIC) assays were
performed with the broth microdilution method, as de-
scribed by the CLSI (Clinical and Laboratory Standards
Institute) in documents M27-A2/CLSI [7] and M38-A [8].
Briefly, 100 μL of each evaluated compound diluted in
RPMI 1640 broth was added to 96-well microplates, with
the final concentrations of the compounds ranging fromFigure 1 Structures of the naphthoquinones used in this study.100 to 0.2 μg/mL (naphthoquinones) and from 64 to
0.06 μg/mL (ketoconazole). Next, 100 μL of an inoculum
containing 2.5 × 103 cells/mL of opportunistic yeasts,
2.5 × 105 cells/mL of dermatophytosis agents or 2.5 ×
104 cells/mL of opportunistic filamentous fungi was added
to the microplate. The microdilution plates were in-
cubated at room temperature (35°C) for 24 to 48 hours
(opportunistic yeasts), 15 days (ringworm agents) or 3 days
(opportunistic filamentous fungi). Visual readings were
performed after 24 hours for the opportunistic yeasts,
after 48 hours for the opportunistic filamentous fungi and
after 120 hours for the dermatophytes. The MIC was
defined as the lowest concentration of the compound
causing 50% inhibition of microorganism growth com-
pared to the control without inhibitors.
Mechanism-of-action assays
The antifungal mechanism of action of naphthoquinone
IVS320 (3a,10b-dihydro-1H-cyclopenta [b] naphtho [2,3-d]
furan-5,10-dione)-dione) was evaluated using the yeast
C. albicans strain ATCC 36232 as a model. The influence
of IVS320 on the cell wall (sorbitol protection assay) and
the effect of ergosterol on the cell membrane (ergosterol
effect assay, K+ efflux assay and leakage of substances ab-
sorbing at 260 nm) were evaluated.
Sorbitol protection assay
We determined the MIC of IVS320 against C. albicans
(ATCC 36232) following CLSI guidelines (from 100 to
0.20 μg/mL) in the presence and absence of 0.8 M sorb-
itol (Sigma-Aldrich), which acts as an osmotic support.
The MICs were determined after 24 hours of incubation
at 35°C [9,10].
Ergosterol effect assay
The MIC of IVS320 for C. albicans (ATCC 36232) was de-
termined following CLSI guidelines in the presence and
Table 1 Microorganisms belonging to the INPA collection and from ATCC used in bioassays
Group of organisms Species (n) Lines of code
Opportunistic yeasts
Candida albicans (n = 1) ATCC 36232
Candida albicans (n = 10)
56/04; 377/06; 839/10; 113/01; 07/10; 143/05; 62/08; 100/04;
322/05; E2/09
Candida parapsilosis (n = 09)
U.1068; U.968/07; U.784/78; U.1047/08; 248/95; U1059/08;
U864/07; U840; U1018/08
Cryptococcus neoformans (n = 5) 12/98; WM 148/10; WM626/10; WM628/10; WM629/10
Cryptococcus gattii (n = 4) WM 161/10; WM178/10; WM179/10; WM 779/10
Dermatophytes
Microsporum canis (n = 10) 93; Tcapt 178; D42; 794; 233; PV 78; Tcapt 209; 274; 88; Tcapt 215/03
Trichophyton rubrum (n = 10) U80/99; U548; U656; U1185; U819; U1077; U855; Tp13; Tp269; Tcorp18
Trichophyton tonsurans (n = 10)
T. capt 300/08; U763/06; U763/06; U654/06; T corp 327/03; U1113/09;
T corp 07; U68; U104; Tp 10 Tp42
Microsporum gypseum (n = 10)
PV 66/99; U1197/08; 680/07; 91/94; Tcorp 401/07; Tcorp 8/10;
PV 56/99; Tcorp 494/08; T corp 282/02; Tcorp 467/08
Opportunistic filamentous fungi
Aspergillus spp (n = 10) U72; U841; U896; U918; U1124; Tp465; PV17; P640; PV672; P218
Fusarium spp (n = 10)
U1048/08; U37/10; U57/10; U998/08; U1028/08; U500/04; U1012/08;
U557/04; U1128/09; U1118
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Aldrich) (200–800 μg/mL), as previously described [10,11].
Amphotericin B was used as a control in this assay.
The MICs were determined after 24 hours of incubation
at 35°C.Potassium efflux assay
C. albicans (ATCC 36232) was grown for 18 hours at 35°C
in RPMI medium. The cells were washed and resuspended
to a concentration of 2.5 × 103 cells/mL in deionized
water, and 1 mL of this suspension was incubated with
IVS320 at the MIC concentration (50 μg/mL) in test tubes
at 35°C for various time periods [12]. C. albicans incu-
bated with deionized water only was used as a control.
After centrifugation, the amount of K+ released into the
supernatant was measured using an atomic absorption
spectrophotometer (AA Spectrophotometer 2380, Perkin-
Elmer).Test for leakage of substances absorbing at 260 nm
C. albicans (ATCC 36232) was grown with shaking at
35°C until the early stationary phase (18 hours of
growth) in RPMI. After incubation, C. albicans cells
were washed and resuspended in MOPS buffer (0.16 M,
pH 7.0). Microtubes (final volume 500 μL) containing an
inoculum of 5 × 104 cells/mL and 1× or 4× MIC concen-
trations of IVS320 were incubated for 6 hours. After 1,
2, 4 or 6 hours of incubation, the microtubes were
centrifuged (5 min at 3,000 rpm), and the absorbance of
the supernatants (100 μL) was measured at 260 nm
(Gene Quant DNA/RNA Eppendorf ). In this assay, theabsorbance due to leakage from cells treated with HClO4
(1.2 M, 100°C, 30 min) was considered 100% [10,13].
Results
Antifungal activity of new naphthoquinones
To investigate the antifungal potential of synthetic naph-
thoquinones, the MIC of each compound was determined
against 89 fungal cultures, including opportunistic yeasts,
dermatophytes and opportunistic filamentous fungi (Table 1).
The compound designated IVS320 (3a,10b-dihydro-1H-
cyclopenta [b] naphtho [2,3-d] furan-5,10-dione)-dione)
presented the lowest MICs for all the tested cultures
and was particularly active against dermatophyte fungi
and yeasts from the genus Cryptococcus (Table 2).
Regarding dermatophyte fungi, the mean MIC ranged
from 5–28 μg/mL; against Cryptococcus spp., the mean
MIC ranged from 3–5 μg/mL.
Investigation of the mechanism of action of IVS320
against C. albicans ATCC 36232
Action on the cell wall
A sorbitol protection assay was conducted to determine
the influence of IVS320 on the integrity of the fungal cell
wall. In this assay, MIC determinations for IVS320 against
C. albicans ATCC 36232 were carried out in parallel in
the presence and absence of sorbitol (0.8 M), which is an
osmotic protectant used for the stabilization of fungal pro-
toplasts. If a compound negatively interferes with the fun-
gal cell wall, it will shift the MIC to a higher value in the
presence of osmotic support [9]. The MIC of IVS320 did
not change in the presence of sorbitol (50 μg/mL) after
72 hours of incubation, which suggests that IVS320 does
Table 2 Minimum inhibitory concentrations (MICs) of new naphthoquinones against different fungal species
Group microorganism Culture (n = 89)
Nor-alfa Nor-beta IVS320 IVS322 ketoconazole
Minimum Inhibitory Concentration (MIC) μg/mL
GM Range GM Range GM Range GM Range GM Range
Yeasts opportunistic
C. albicans (n = 10) 66 6.3 – 100 86 6.3 – 100 35 3.1-50 78 6,3-100 1 0,125-2
C. parapsilosis (n = 10) 50 - 75 25-100 25 13-50 86 25-100 0,06 -
C. neoformans (n = 05) 15 12.5-50 100 100 5 1,56-6,25 56 25-50 - -
C. gattii (n = 04) 25 12.5-50 100 100 3 1,56-6.25 44 25-50 - -
Dermatophytes
T. rubrum (n = 10) 16 6.3-25 19 6.3-100 5 3,3-12,5 10 6,3-25 29 2-64
M. canis (n = 10) 43 25-50 30 12,5-100 8 3,1-12,5 24 3,1-100 5 1-16
M. gypseum (n = 10) 78 50-100 67 25-100 28 12,5-50 122 50-200 5 2-8
T. tonsurans (n = 10) 35 12,5-50 34 6.3-200 8 3,11-25 38 25-50 1 0,5-4
Filamentous opportunistic
Fusarium sp. (n = 10) 117 50-200 67 25-100 36 25-50 103 50-200 6 1-16
Aspergillus sp. (n = 10) 90 50-100 75 50-100 33 6,3-50 85 50-100 32 4-64
GM = geometric mean; − test not performed, n = number of different isolates.
The geometric mean and range for each compound against each group of fungal species are reported.
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synthesis.
Action on ergosterol
An ergosterol assay was used to determine whether
IVS320 induces changes in the fungal membrane by
interacting with ergosterol. This assay has been shown
to identify compounds that bind ergosterol in fungal
membranes and is based on the addition of exogenous
ergosterol. A compound that has an affinity for ergos-
terol rapidly forms complexes with free ergosterol, thus
preventing interactions with ergosterol in the fungal
membrane; as a result, the MIC of the tested compound
increases. The results showed that the MIC of IVS320
against C. albicans ATCC 36232 did not change in the
presence of different concentrations (200 to 800 μg/mL)
of exogenous ergosterol (Figure 2), suggesting that
IVS320 does not act by interacting with ergosterol. InFigure 2 Effects of exogenous ergosterol (200–800 μg/mL) on
the MIC of IVS320 and amphotericin B against C. albicans ATCC
36232. On the y-axis: 1 = 1× MIC, 2 = 2× MIC, 3 = 3× MIC, 4 = 4× MIC.contrast, there was a 4× MIC increase with amphotericin
B, which is known to have a strong affinity for ergosterol
and served as the positive control in this assay [14].
Action on potassium efflux
A potassium efflux test was conducted to evaluate
whether compound IVS320 interferes with the osmotic
balance of C. albicans (ATCC 36232). This assay is based
on the fact that the cell membrane is responsible for
maintaining intracellular K+, so an increase in extracellu-
lar K + indicates cell membrane disruption. As shown in
Figure 3, the efflux of K+ from C. albicans (ATCC 36232)
cells into the extracellular medium increased with IVS320
treatment, whereas the extracellular K+ concentration in
the control culture remained constant during incubation.
The time course of K+ efflux into the culture supernatant
indicated that the permeability of the fungal membrane
increased up to 4 hours.Figure 3 Effect of IVS320 on K+ efflux from C. albicans ATCC
36232.
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The interference of IVS320 with the membrane of
C. albicans ATCC 36232 was determined by evaluating
the leakage of substances that absorb at 260 nm from
the membrane. Membrane rupture causes the release/
leakage of intracellular components from the fungal cell,
which can then be measured. Nucleotides, which exhibit
a strong absorbance at 260 nm, are among the compo-
nents that can be monitored to detect leakage. IVS320
(1× MIC and 4× MIC) was added to cell suspensions of
C. albicans, and the samples were examined after va-
rious time intervals (1, 2, 4 and 6 hours). The results
showed that 1× IVS320 MIC caused increases of 6, 9, 17
and 21% at 1, 2, 4 and 6 hours, respectively, compared
to the perchloric acid control, which is considered to
produce 100% cell leakage (Figure 4). Furthermore, the
4× MIC treatment caused a 2.6× increase in nucleotide
leakage, resulting in 14, 25, 42 and 61% increases in
leakage at 1, 2, 4 and 6 hours, respectively, compared to
the perchloric acid control.
Discussion
The 1,4-naphthoquinone structure is common in various
natural products and clinically used drugs that are asso-
ciated with antifungal activity. Previous studies have
demonstrated the potential of this class of compounds.
Importantly, the work of Sassaki et al. [15] evaluated the
antifungal activities of 1,4-naphthoquinone derivatives
and obtained MICs of 8 μg/mL and 16 μg/mL against
cultures of Candida albicans and Candida parapsilosis,
respectively. Sheng et al. 2011 [5] studied structural
changes and the structure/activity of 1,4-naphthoqui-
none, showing that the introduction of side chains con-
taining sulfur, oxygen or nitrogen atoms at position C2
and/or C3 led to an increase in antifungal activity. These
researchers also evaluated the activity of 17 compounds
with different side chains and found three compounds
that showed broad antifungal activity. One compound,Figure 4 Leakage of substances absorbing at 260 nm from C.
albicans ATCC 36232 incubated (1–6 hours) with 1× and 4×
MICs for IVS320.[2-chloro-3-((4-hydroxyphenyl) amino) naphthalene-1,4-
dione], presented MICs of 3.12 μg/mL, 1.56 μg/mL and
0.78 μg/mL against Aspergillus fumigatus, C. albicans
and C. neoformans, respectively. The antifungal potential
of 1,4-naphthoquinone derivatives was also confirmed
by Yamashita et al. [16] and Kategaonkar [17].
In the present work, all tested naphthoquinones exhib-
ited antifungal activity. These results corroborate those of
Freire et al. [6], who observed the inhibitory activity of
these compounds against C. albicans, particularly Nor-α.
Nonetheless, these findings require confirmation across a
large number of C. albicans isolates as well as other fungal
classes. The results of the present study clearly demon-
strate the potential of these antifungals against a large
number of different isolates of pathogenic species.
IVS320 exhibited the lowest MIC against dermato-
phytes and Cryptococcus spp. These results are import-
ant given that this is the first study evaluating the
antifungal action of this compound against these agents.
The importance of new drugs for the treatment of der-
matophytosis is highlighted by the fact that this disease
affects approximately 40% of the world population, that
only a small number of drugs are currently available for
treatment, that azoles and allylamines have adverse gas-
trointestinal effects and that there is a high frequency of
recurrence [18,19]. Amphotericin B and flucytosine are
widely used for the treatment of cryptococcosis; how-
ever, the toxicity of both of these therapeutics is well
described, and therapeutic failure is often observed [20].
Due to the robust results for IVS320, this naphthoqui-
none was selected for assessing its antifungal mechanism
of action. A strain of Candida albicans (ATCC 36232)
was selected due to the importance of this species in the
epidemiology of fungal infections, and the use of an
ATCC microorganism will facilitate reproduction of the
work reported here [21].
IVS320 did not alter the structure of the fungal cell
wall but did change the permeability of the cell mem-
brane (efflux of K+ and leakage of substances that absorb
260 nm), which was not related to binding with ergos-
terol. These results are similar to those obtained by
Emadi et al. [22], who evaluated the possible mechanism
of action of bis-naphthoquinones and concluded that
these compounds cause membrane depolarization.
Accordingly, the toxicity of IVS320 should be exten-
sively evaluated against human cells, even though studies
by Freire et al. [6] showed that this compound exhibited
no significant hemolytic activity against mouse erythro-
cytes and no cytotoxicity against human fibroblasts (NIH
3 T3) at concentrations between 12.5 and 50 μg/mL.
The results of the present study are relevant because
they will motivate new in vivo research focusing on the
development of new antifungal agents as alternatives for
the treatment of ringworm and opportunistic mycoses.
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